


The background of the slide features a close-up, top-down view of several pills and a stethoscope. The pills are in various colors: white, yellow, and pink/red. Some are oval-shaped, while others are capsules. A silver stethoscope with a brown leather-like handle is positioned on the right side, its chest piece resting on a yellow pill. The overall lighting is soft and clinical.

Bakers Union and FELRA Health and Welfare Fund

Quarterly Review
January – March 2024

June 12, 2024

Today's Topics

1. Key Discussion Topics
2. Performance Summary
3. Trend
4. Top Disease States
5. Rebates
6. Clinical Outcomes
 - UM Outcomes
 - Vigilant Outcomes
 - Variable Copay Outcomes

Your OptumRx Team

Paul Marcus

VP, Client Management
Labor & Trust

Holly Agoney

Strategic Account Executive
Labor & Trust

Autumn Leblanc

Pharmacy Account
Manager
Labor & Trust

David Payton

Pharmacy Service
Specialist
Labor & Trust

Current Plan Design

☐ Deductible, Ben Max, MOOP, Copays

Plan 1 (group BFWRX):	
Deductible:	This plan has no deductible.
Benefit Maximum:	\$2,000 per year for Growth Hormones medications only
Max out of Pocket:	\$2,850 Individual / \$5,700 Family

Plan 2 (group BFWRX2) & Plan 3 (group BFWRX3):	
Deductible:	This plan has no deductible.
Benefit Maximum:	\$2,000 per year for Growth Hormones medications only
Max out of Pocket:	\$1,850 Individual / \$3,700 Family

Co-pays			
Plan 1 (group BFWRX) & Plan 2 (group BFWRX2):			
	Retail		Mail
*Generic:	\$10	*Generic:	\$20
*Brand:	\$15	*Brand:	\$30
*NP Brand:	\$30	*NP Brand:	\$60
*Specialty:	Run trial claim for co-pay		*Specialty: N/A

Plan 3 (group BFWRX3):		
Retail / Mail		
*Generic:	5%	(\$5 min.)
*Brand:	15%	(\$15 min.)
*NP Brand:	25%	(\$25 min.)
*Specialty:	Run trial claim for co-pay	

☐ Effective 7/1/19

- ☐ Diabetes Program
- ☐ Comprehensive Ums
- ☐ Vigilant Program
- ☐ RxOTC Program

☐ Effective 8/1/2020

- ☐ Orphan Drug Program

☐ Effective 3/1/2021

- ☐ Opioid Mgmt – tighter refill window & UMs

☐ Effective 7/1/2021

- ☐ Premium Formulary
- ☐ Mandatory Mail (MSS)

☐ Effective 1/1/2022

- ☐ Split-fill/Smart-fill

☐ Effective 3/1/2022

- ☐ CCAA/VCS

☐ Effective 5/15/23

- ☐ Price Edge

Key Discussion Topics



- ❑ Per Member Per Month (PMPM) trend = 7.8% Specialty trend = negative -(20.9)%
- ❑ Specialty represents 0.7% of claims

- ❑ Top 5 disease states accounted for 71% of total plan paid
 - ❑ Top traditional disease state: Diabetes
 - ❑ Top specialty disease state: Inflammatory Conditions

- ❑ Rebates – Jan – March 2024
 - ❑ Estimated - \$46,800

- ❑ Clinical Outcomes savings
 - ❑ **UM (PA, ST, QL)** – April 2023 – March 2024
 - ❑ Savings = \$160,200
 - ❑ **Vigilant** – April 2023 – March 2024
 - ❑ Savings = \$22,366
 - ❑ **Variable Copay** – Jan – March 2024
 - ❑ Savings = \$6,498

Key Statistics

Key Statistics – Overall Performance Summary

549

Avg. eligible members

Key statistics with benchmark comparison

Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was 7.8%, compared to the benchmark trend of 6.7%
- Member Paid Share changed by -4.2% period over period, compared to the benchmark of -7.3%

Benchmark comparison 1

LABOR AND TRUST

Benchmark comparison 2

COMMERCIAL

the benchmark of -7.3%

				LABOR AND TRUST		COMMERCIAL	
Key statistics	Curr	Prev	Percent change	Curr	Percent change	Curr	Percent change
Average age	45.0	43.8	2.6%	38.7	-0.5%	35.9	0.0%
Plan paid PMPM	\$169.65	\$157.32	7.8%	\$123.73	6.7%	\$142.02	10.6%
Plan paid per Rx	\$157.86	\$161.49	-2.2%	\$166.56	4.4%	\$172.54	6.9%
Rxs PMPM	1.075	0.974	10.3%	0.743	2.3%	0.823	3.4%
Average days supply	31.6	30.9	2.1%	40.9	0.0%	39.7	-0.2%
Days supply PMPM	34.0	30.1	12.7%	30.4	2.3%	32.6	3.2%
Member paid share	8.8%	9.2%	-4.2%	8.0%	-7.3%	13.8%	-2.7%
Member paid per Rx	\$15.27	\$16.38	-6.8%	\$14.48	-3.9%	\$27.62	3.6%
Generic dispensing rate	85.1%	85.4%	-0.3%	89.0%	1.0%	88.3%	1.4%
GDR-without Vaccines	86.3%	86.5%	-0.2%	89.6%	1.0%	89.1%	1.3%
Home delivery rate	7.1%	6.1%	16.7%	10.4%	-0.3%	6.1%	1.5%
Retail 90 rate	1.9%	1.8%	4.1%	16.7%	2.4%	19.0%	-0.8%
Percent of specialty plan paid	29.8%	40.6%	-26.7%	45.1%	3.8%	51.7%	3.3%

Total Rxs

CURRENT

1,770

PREVIOUS

1,735

PERCENT CHANGE

2.0%

Total plan paid

CURRENT

\$279,418

PREVIOUS

\$280,188

PERCENT CHANGE

-0.3%

Utilizers

CURRENT

273

PREVIOUS

305

PERCENT CHANGE

-10.5%

Specialty Key Statistics

Key statistics with benchmark comparison

Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was -20.9%, compared to the benchmark trend of 10.8%
- Member Paid Share changed by 2.0% period over period, compared to the benchmark of -10.1%

Benchmark comparison 1

LABOR AND TRUST ▼

Benchmark comparison 2

COMMERCIAL ▼

the benchmark of -10.1%

Key statistics	LABOR AND TRUST			COMMERCIAL			
	Curr	Prev	Percent change	Curr	Percent change	Curr	Percent change
Plan Paid PMPM	\$50.58	\$63.95	-20.9%	\$55.75	10.8%	\$73.48	14.3%
Plan paid per Rx	\$6,408.50	\$6,327.51	1.3%	\$8,349.99	3.5%	\$7,715.74	3.7%
Rxs PMPM	0.008	0.010	-21.9%	0.007	7.0%	0.010	10.2%
Average days supply	32.3	28.2	14.5%	32.5	1.6%	31.4	1.3%
Days supply PMPM	0.3	0.3	-10.6%	0.2	8.7%	0.3	11.6%
Member paid share	7.3%	7.2%	2.0%	4.3%	-10.1%	8.6%	-4.2%
Member paid per Rx	\$505.62	\$488.83	3.4%	\$374.18	-7.4%	\$726.95	-1.0%
Generic dispensing rate	0.0%	0.0%	0.0%	9.1%	11.0%	8.1%	0.9%
Home delivery rate	0.0%	5.6%	-100.0%	0.6%	-90.2%	0.3%	-92.0%
Retail 90 rate	7.7%	0.0%	0.0%	5.5%	12.4%	4.9%	7.5%

Total Rxs

CURRENT

13

PREVIOUS

18

PERCENT CHANGE

-27.8%

Total plan paid

CURRENT

\$83,310

PREVIOUS

\$113,895

PERCENT CHANGE

-26.9%

Utilizers

CURRENT

5

PREVIOUS

6

PERCENT CHANGE

-16.7%

Trend Summary

Trend Summary

Trend

Plan paid PMPM has increased 7.8% over the previous period driven primarily by drug mix in traditional and drug mix for specialty.

Specialty represents 0.7% of claims.



+1.1% over benchmark



+23.9% over benchmark



-31.7% under benchmark

Top Disease States & Top 20 Drugs


Top Disease States



Top 5 disease states account for 71% of total Plan Paid

- Diabetes accounts for 28.4% of total plan paid, with trend driven by Drug Mix. MOUNJARO was the top drug
- Inflammatory Conditions accounts for 19.4% of total plan paid, with trend driven by Drug Mix. DUPIXENT was the top drug

Sort by: Plan Paid



Top 20 Drugs by Plan Cost

All meds are Brands except indicated with a "G" for generic

Specialty

Rank													Trend components		
Cu	Pv	Bench	Drug name	Therapy class	Utilzr	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr plan paid PMPM	Prev plan paid PMPM	Bench plan paid PMPM	% Trend	Top driver	% Top driver
1	2	7	DUPIXENT	Chronic Inflammatory Disease	3	10	28.0	\$32,751	\$3,275.10	\$19.89	\$13.85	\$2.99	43.6%	Utilzn	20.2%
2	-	68	KISQALI	Oncology	1	2	28.0	\$29,172	\$14,586.04	\$17.71	\$0.00	\$0.28	-	-	-
3	16	5	MOUNJARO	GLP-1 Receptor Agonists	8	19	34.1	\$22,397	\$1,178.78	\$13.60	\$1.67	\$3.60	715.4%	Utilzn	734.2%
4	3	1	HUMIRA PEN	Chronic Inflammatory Disease	1	1	84.0	\$21,387	\$21,387.42	\$12.99	\$12.01	\$6.69	8.1%	Utilzn	8.1%
5	12	349	STRIBILD	HIV-Multiclass Combo	1	4	30.0	\$16,286	\$4,071.50	\$9.89	\$2.18	\$0.05	354.0%	Utilzn	332.5%
6	6	4	JARDIANCE	SGLT-2 Inhibitors & Combos	8	18	40.0	\$12,362	\$686.79	\$7.51	\$5.46	\$3.90	37.5%	Utilzn	44.2%
7	-	772	SANTYL	Enzymes - Topical	1	1	30.0	\$7,687	\$7,687.26	\$4.67	\$0.00	\$0.01	-	-	-
8	10	2	OZEMPIC	GLP-1 Receptor Agonists	3	6	38.0	\$7,303	\$1,217.16	\$4.43	\$3.35	\$6.35	32.3%	Utilzn	24.5%
9	50	11	FARXIGA	SGLT-2 Inhibitors & Combos	6	11	30.0	\$6,132	\$557.50	\$3.72	\$0.61	\$1.82	513.2%	Utilzn	494.7%
10	18	10	BIKTARVY	HIV-Multiclass Combo	1	2	30.0	\$5,970	\$2,984.94	\$3.62	\$1.57	\$2.31	131.0%	Utilzn	116.3%
11	-	24	RYBELSUS	GLP-1 Receptor Agonists	2	6	30.0	\$5,620	\$936.69	\$3.41	\$0.00	\$0.97	-	-	-
12	22	8	ELIQUIS	Oral Anticoagulants	3	9	30.0	\$5,125	\$569.42	\$3.11	\$1.43	\$2.84	117.7%	Utilzn	94.6%
13	20	17	WEGOVY	GLP-1 Anti-Obesity Agents	2	4	28.0	\$5,056	\$1,264.05	\$3.07	\$1.47	\$1.36	108.7%	Utilzn	116.3%
14	33	23	TRELEGY ELLIPTA	Inhaled Asthma/COPD Combo	3	7	30.0	\$4,421	\$631.61	\$2.68	\$1.03	\$1.03	160.2%	Utilzn	152.3%
15	54	81	DEXCOM G6 SENSOR	Diabetes Monitoring and Testing Supplies	3	6	50.0	\$3,405	\$567.56	\$2.07	\$0.52	\$0.25	297.5%	Utilzn	260.5%
16	36	276	GLYXAMBI	SGLT-2 Inhibitors & Combos	1	2	90.0	\$3,284	\$1,641.97	\$1.99	\$0.92	\$0.06	117.3%	Utilzn	116.3%
17	40	19	XARELTO	Oral Anticoagulants	3	2	90.0	\$3,057	\$1,528.37	\$1.86	\$0.84	\$1.31	121.7%	Utilzn	116.3%
18	11	36	JANUMET	DPP-4 Inhibitors & Combos	2	5	30.0	\$2,742	\$548.40	\$1.66	\$2.35	\$0.55	-29.1%	Utilzn	-32.4%
19	23	310	SOLIQUA 100/ 33	Insulin	1	1	90.0	\$2,611	\$2,610.83	\$1.59	\$1.39	\$0.05	13.6%	Utilzn	8.1%
20	-	418	EUFLEXXA	Osteoarthritis	1	1	30.0	\$2,202	\$2,202.43	\$1.34	\$0.00	\$0.04	-	-	-
Total					44	117	36.4	\$198,972	\$1,700.61	\$120.81	\$50.64	\$36.45	138.6%		111.8%
Plan Total					273	1,770	31.6	\$279,418	\$157.86	\$169.65	\$157.32	\$123.73	7.8%		12.7%

Rebates


Rebate Performance Summary

Bakers Union and FELRA Health and Welfare Fund

Outcomes date range: Jan - Mar 2024

Benchmark: LABOR AND TRUST

Current rebate value: \$28.41 PMPM



Rebate impact on Plan Paid PMPM

Managing drug spend to a lowest net cost PMPM is achieved through adoption of high performing formulary strategies and driving to lowest net cost products when clinically appropriate. Bakers Union and FELRA Health and Welfare Fund's members adherence to the formulary has earned an offset on PMPM costs, yielding a net plan paid PMPM of \$141.24, versus plan paid PMPM of \$169.65.

Net financial PMPM performance

	Drug cost	Member Paid	Plan Paid	Rebates	Net plan paid
Traditional	\$131.47	\$12.42	\$119.07	\$22.33	\$96.74
Specialty	\$54.57	\$3.99	\$50.58	\$6.08	\$44.51
Total	\$186.04	\$16.41	\$169.65	\$28.41	\$141.24

Total estimated rebate yield for reporting period: \$46.8K

Rebate Performance by Disease State

Disease ↕	Drug cost PMPM ↕	Member paid PMPM ↕	Plan paid PMPM ↕	Rebates PMPM ↕	Net plan paid PMPM ↕	Rebate offset ↕
Diabetes	\$50.66	\$2.43	\$48.23	\$14.01	\$34.21	29.1%
Inflammatory Conditions	\$36.84	\$3.97	\$32.87	\$6.08	\$26.79	18.5%
Asthma / COPD	\$8.46	\$0.43	\$8.03	\$2.37	\$5.65	29.6%
Blood Clot Prevention/Stroke Prevention	\$0.00	\$0.00	\$0.00	\$1.48	\$0.00	0.0%
Diabetic Supplies	\$4.53	\$0.29	\$4.23	\$1.03	\$3.20	24.4%
Cardiovascular	\$9.14	\$1.92	\$7.22	\$0.86	\$6.37	11.8%
HIV	\$15.11	\$1.21	\$13.89	\$0.62	\$13.27	4.5%
Weight Loss	\$3.33	\$0.17	\$3.17	\$0.41	\$2.75	13.0%
Neurologic	\$0.87	\$0.13	\$0.74	\$0.31	\$0.43	41.7%
Overactive Bladder / Incontinence	\$1.18	\$0.06	\$1.13	\$0.21	\$0.92	18.3%
Kidney Disease	\$1.28	\$0.04	\$1.24	\$0.21	\$1.04	16.6%
Severe Allergic Reaction	\$0.25	\$0.01	\$0.24	\$0.10	\$0.14	43.1%
Ophthalmic Agents	\$0.65	\$0.09	\$0.56	\$0.10	\$0.46	18.4%
Antibiotics	\$1.06	\$0.34	\$0.71	\$0.10	\$0.61	14.5%
Glaucoma	\$1.08	\$0.11	\$0.97	\$0.10	\$0.87	10.6%
Osteoarthritis	\$1.35	\$0.01	\$1.34	\$0.10	\$1.23	7.7%
Depression	\$2.69	\$0.61	\$2.08	\$0.10	\$1.98	5.0%
Misc Skin Condition	\$5.37	\$0.15	\$5.22	\$0.10	\$5.12	2.0%
Gastrointestinal, Misc	-\$0.25	\$0.05	-\$0.30	\$0.10	-\$0.40	-34.6%


Clinical Outcomes

UM Outcomes

Utilization management savings: \$23.77 PMPM

Your program savings: **\$160.2K**

Ensuring patients meet appropriate clinical criteria when initiating medication therapy not only helps to ensure that the patient is being treated safely according to guidelines, but also drives significant savings for both Bakers Union and FELRA Health and Welfare Fund and for members. Bakers Union and FELRA Health and Welfare Fund has realized over \$160.2K in savings. Based on a study by OptumRx, leveraging UM strategies that drive members to appropriate and often lower cost medications for treatment can save a member up to \$620 annually in out of pocket copayments.



Prior authorization

PMPM SAVINGS

\$6.81

NUMBER OF MEMBERS IMPACTED

34

NUMBER OF INTERVENTIONS

42

Quantity limits

PMPM SAVINGS

\$12.67

NUMBER OF MEMBERS IMPACTED

15

NUMBER OF INTERVENTIONS

16

Step therapy

PMPM SAVINGS

\$4.28

NUMBER OF MEMBERS IMPACTED

81

NUMBER OF INTERVENTIONS

104

QL savings is based only on Maximum Daily Dose edits.

Vigilant Outcomes



Total program savings: \$3.32 PMPM

Vigilant Drug Outcomes – Cost Avoidance

By leveraging the Vigilant Drug Program, Bakers Union and FELRA Health and Welfare Fund has:

- Avoided \$22.4K in pharmacy spend
- Switched 12 claims to lower cost alternatives
- 5 claims were abandoned



TOTAL PLAN PAID SAVINGS
\$22,366

TOTAL PROGRAM SAVINGS
2.0%

TOTAL MEMBERS IMPACTED
17

Savings by Vigilant Drug List

Sort by: Members impacted Plan paid PMPM savings

Vigilant drug list	PMPM savings	Members impacted	Interventions
Clinical Duplicates	\$0.53	7	7
High Cost Brands with Generics	\$2.74	4	4
High Cost Generics	-\$0.02	3	3
New Drugs to Market	\$0.07	3	3

Variable Copay (VCS) Outcomes

Total program savings: \$3.95 PMPM

Variable copay program savings outcomes

With the OptumRx Variable Copay program, Bakers Union and FELRA Health and Welfare Fund has realized:

- \$6,498 in Plan Paid savings
- \$1,083.00 average Plan Paid per impacted prescription
- 3 total impacted utilizers

PLAN PAID SAVINGS

\$6,498

PLAN PAID SAVINGS PER IMPACTED RX

\$1,083.00

Top 5 drugs based on: Plan paid savings

DUPIXENT

IMPACTED RXS

6

IMPACTED UTILIZERS

3

PLAN PAID SAVINGS

\$6,498


Appendix

Trend Components

Total trend: **7.8%**

- Bakers Union and FELRA Health and Welfare Fund's overall trend of 7.8% was 1.1% higher than benchmark
- Traditional spend influenced the trend contributing 208.4% (177.8% higher than benchmark)
- Specialty trend contributed -108.4% (177.8% lower than benchmark)


Benchmark comparison: **LABOR AND TRUST**



Traditional trend: **27.5%**

- Traditional trend contributed 208.4% to the overall trend (7.8%)
- Traditional accounts for 70.2% of overall total plan paid and was up from 59.4% in the prior period


Benchmark comparison: **LABOR AND TRUST**



Specialty trend: **-20.9%**

- Specialty trend contributed -108.4% to the overall trend (7.8%)
- Specialty accounts for 29.8% of overall total plan paid and was down from 40.6% in the prior period

Benchmark comparison: **LABOR AND TRUST**



Top 20 traditional

All meds are Brands except indicated with a “G” for generic

Rank			Trend components													
Cu↕	Pv↕	Bench↕	Drug name↕	Therapy class↕	Utilizr↕	Rxs↕	Avg days supply↕	Total plan paid↕	Plan paid per Rx↕	Curr plan paid PMPM↕	Prev plan paid PMPM↕	Bench plan paid PMPM↕	% Trend↕	Top driver↕	% Top driver↕	
1	10	3	MOUNJARO	★	GLP-1 Receptor Agonists	8	19	34.1	\$22,397	\$1,178.78	\$13.60	\$1.67	\$3.60	715.4%	Utilizr	734.2%
2	6	186	STRIBILD		HIV-Multiclass Combo	1	4	30.0	\$16,286	\$4,071.50	\$9.89	\$2.18	\$0.05	354.0%	Utilizr	332.5%
3	2	2	JARDIANCE	★	SGLT-2 Inhibitors & Combos	8	18	40.0	\$12,362	\$686.79	\$7.51	\$5.46	\$3.90	37.5%	Utilizr	44.2%
4	-	486	SANTYL		Enzymes - Topical	1	1	30.0	\$7,687	\$7,687.26	\$4.67	\$0.00	\$0.01	-	-	-
5	4	1	OZEMPIC	★	GLP-1 Receptor Agonists	3	6	38.0	\$7,303	\$1,217.16	\$4.43	\$3.35	\$6.35	32.3%	Utilizr	24.5%
6	44	7	FARXIGA	★	SGLT-2 Inhibitors & Combos	6	11	30.0	\$6,132	\$557.50	\$3.72	\$0.61	\$1.82	513.2%	Utilizr	494.7%
7	12	6	BIKTARVY		HIV-Multiclass Combo	1	2	30.0	\$5,970	\$2,984.94	\$3.62	\$1.57	\$2.31	131.0%	Utilizr	116.3%
8	-	13	RYBELSUS	★	GLP-1 Receptor Agonists	2	6	30.0	\$5,620	\$936.69	\$3.41	\$0.00	\$0.97	-	-	-
9	16	4	ELIQUIS		Oral Anticoagulants	3	9	30.0	\$5,125	\$569.42	\$3.11	\$1.43	\$2.84	117.7%	Utilizr	94.6%
10	14	9	WEGOVY		GLP-1 Anti-Obesity Agents	2	4	28.0	\$5,056	\$1,264.05	\$3.07	\$1.47	\$1.36	108.7%	Utilizr	116.3%
11	27	12	TRELEGY ELLIPTA		Inhaled Asthma/COPD Combo	3	7	30.0	\$4,421	\$631.61	\$2.68	\$1.03	\$1.03	160.2%	Utilizr	152.3%
12	48	40	DEXCOM G6 SENSOR	★	Diabetes Monitoring and Testing Supplies	3	6	50.0	\$3,405	\$567.56	\$2.07	\$0.52	\$0.25	297.5%	Utilizr	260.5%
13	30	145	GLYXAMBI	★	SGLT-2 Inhibitors & Combos	1	2	90.0	\$3,284	\$1,641.97	\$1.99	\$0.92	\$0.06	117.3%	Utilizr	116.3%
14	34	10	XARELTO		Oral Anticoagulants	3	2	90.0	\$3,057	\$1,528.37	\$1.86	\$0.84	\$1.31	121.7%	Utilizr	116.3%
15	5	16	JANUMET	★	DPP-4 Inhibitors & Combos	2	5	30.0	\$2,742	\$548.40	\$1.66	\$2.35	\$0.55	-29.1%	Utilizr	-32.4%
16	17	160	SOLIQUA 100/ 33	★	Insulin	1	1	90.0	\$2,611	\$2,610.83	\$1.59	\$1.39	\$0.05	13.6%	Utilizr	8.1%
17	-	222	EUFLEXXA		Osteoarthritis	1	1	30.0	\$2,202	\$2,202.43	\$1.34	\$0.00	\$0.04	-	-	-
18	46	72	ADVAIR HFA		Inhaled Asthma/COPD Combo	3	6	30.0	\$2,112	\$352.07	\$1.28	\$0.57	\$0.15	124.1%	Utilizr	224.4%
19	23	124	VELPHORO		Phosphate Binder Agents	1	2	30.0	\$2,047	\$1,023.29	\$1.24	\$1.09	\$0.07	13.7%	Utilizr	8.1%
20	24	49	TRESIBA FLEXTOUCH	★	Insulin	1	4	19.0	\$1,960	\$489.96	\$1.19	\$1.09	\$0.22	9.3%	Cost	10.4%
Total						40	116	35.8	\$121,780	\$1,049.83	\$73.94	\$27.54	\$26.93	168.5%		120.0%
Plan Total						273	1,757	31.6	\$196,107	\$111.61	\$119.07	\$93.37	\$87.98	27.5%		20.9%

Top 20 specialty

All meds are Brands except indicated with a “G” for generic

Rank													Trend components		
Cu ↕	Pv ↕	Bench ↕	Drug name ↕	Therapy class ↕	Utilizr ↕	Rxs ↕	Avg days supply ↕	Total plan paid ↕	Plan paid per Rx ↕	Curr plan paid PMPM ↕	Prev plan paid PMPM ↕	Bench plan paid PMPM ↕	% Trend ↕	Top driver ↕	% Top driver ↕
1	2	4	DUPIXENT	Chronic Inflammatory Disease	3	10	28.0	\$32,751	\$3,275.10	\$19.89	\$13.85	\$2.99	43.6%	Utilizr	20.2%
2	-	35	KISQALI	Oncology	1	2	28.0	\$29,172	\$14,586.04	\$17.71	\$0.00	\$0.28	-	-	-
3	3	1	HUMIRA PEN	Chronic Inflammatory Disease	1	1	84.0	\$21,387	\$21,387.42	\$12.99	\$12.01	\$6.69	8.1%	Utilizr	8.1%
Total						5	13	32.3	\$83,310	\$6,408.50	\$50.58	\$63.95	\$17.22	-20.9%	-12.8%
Plan Total						5	13	32.3	\$83,310	\$6,408.50	\$50.58	\$63.95	\$55.75	-20.9%	-12.8%